Chengdu Huasun Group Inc Ltd - Asset Resilience Ratio

Latest as of June 2025: 0.31%

Chengdu Huasun Group Inc Ltd (000790) has an Asset Resilience Ratio of 0.31% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 000790 liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥6.56 Million
≈ $959.95K USD Cash + Short-term Investments

Total Assets

CN¥2.09 Billion
≈ $305.40 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (1995–2024)

This chart shows how Chengdu Huasun Group Inc Ltd's Asset Resilience Ratio has changed over time. See net assets of Chengdu Huasun Group Inc Ltd for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Chengdu Huasun Group Inc Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Chengdu Huasun Group Inc Ltd (000790) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥6.56 Million 0.31%
Total Liquid Assets CN¥6.56 Million 0.31%

Asset Resilience Insights

  • Limited Liquidity: Chengdu Huasun Group Inc Ltd maintains only 0.31% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Chengdu Huasun Group Inc Ltd Industry Peers by Asset Resilience Ratio

Compare Chengdu Huasun Group Inc Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Ipsen SA
PA:IPN
Drug Manufacturers - Specialty & Generic 21.63%
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
Drug Manufacturers - Specialty & Generic 20.44%
Neuland Laboratories Limited
NSE:NEULANDLAB
Drug Manufacturers - Specialty & Generic 6.06%
Curaleaf Holdings Inc.
TO:CURA
Drug Manufacturers - Specialty & Generic 3.73%
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
Drug Manufacturers - Specialty & Generic 35.10%
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424
Drug Manufacturers - Specialty & Generic 2.09%
Shandong Shanda Wit Science and Technology Co Ltd
SHE:000915
Drug Manufacturers - Specialty & Generic 25.22%
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
SHG:688505
Drug Manufacturers - Specialty & Generic 11.06%

Annual Asset Resilience Ratio for Chengdu Huasun Group Inc Ltd (1995–2024)

The table below shows the annual Asset Resilience Ratio data for Chengdu Huasun Group Inc Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.29% CN¥6.56 Million
≈ $959.95K
CN¥2.25 Billion
≈ $329.13 Million
-1.66pp
2020-12-31 1.95% CN¥22.23 Million
≈ $3.25 Million
CN¥1.14 Billion
≈ $166.82 Million
-1.90pp
1996-12-31 3.85% CN¥7.11 Million
≈ $1.04 Million
CN¥184.48 Million
≈ $27.00 Million
-1.62pp
1995-12-31 5.48% CN¥8.64 Million
≈ $1.26 Million
CN¥157.76 Million
≈ $23.09 Million
--
pp = percentage points

About Chengdu Huasun Group Inc Ltd

SHE:000790 China Drug Manufacturers - Specialty & Generic
Market Cap
$393.37 Million
CN¥2.69 Billion CNY
Market Cap Rank
#13831 Global
#4299 in China
Share Price
CN¥4.31
Change (1 day)
+2.38%
52-Week Range
CN¥3.58 - CN¥4.60
All Time High
CN¥21.66
About

Chengdu huasun technology group Inc. , LTD. manufactures and sells medicines, bio-pharmaceutical products, and building steel structures. The company manufactures modern Chinese medicines, Chinese patent medicines, chemical medicines, and drugs. It also engages in the research and development, production, and sale of biological products and biotechnology drugs; and medicines for the treatment of … Read more